Home » Stocks » TRVI

Trevi Therapeutics, Inc. (TRVI)

Stock Price: $2.97 USD -0.04 (-1.33%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $2.94 -0.03 (-1.01%) Jan 22, 5:18 PM
Market Cap 54.59M
Revenue (ttm) n/a
Net Income (ttm) -29.77M
Shares Out 18.13M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $2.97
Previous Close $3.01
Change ($) -0.04
Change (%) -1.33%
Day's Open 2.96
Day's Range 2.91 - 3.03
Day's Volume 95,454
52-Week Range 1.71 - 7.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 months ago

Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

PRISM Trial of Haduvio ™ for Severe Pruritus in Patients with Prurigo Nodularis 

GlobeNewsWire - 2 months ago

NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Hadu...

GlobeNewsWire - 2 months ago

Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET

GlobeNewsWire - 3 months ago

Expands Management Team to Support Clinical Development and Commercial Strategy of Haduvio™ in Multiple Late Stage Programs Expands Management Team to Support Clinical Development and Commerci...

GlobeNewsWire - 4 months ago

NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of H...

Seeking Alpha - 5 months ago

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial

GlobeNewsWire - 5 months ago

NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Ha...

GlobeNewsWire - 6 months ago

Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design

GlobeNewsWire - 6 months ago

Seasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience Seasoned biopharmaceutical executive with over 20 years of executive leader...

GlobeNewsWire - 7 months ago

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of na...

GuruFocus - 7 months ago

Analysts on Wall Street recommend buying shares of Trevi Therapeutics Inc (NASDAQ:TRVI) and Carter Bank & Trust (NASDAQ:CARE), even though their share prices have lost more than 59% over the p...

Other stocks mentioned: CARE
GlobeNewsWire - 11 months ago

Seasoned biopharmaceutical executive with over 30 years of drug development experience Seasoned biopharmaceutical executive with over 30 years of drug development experience

Seeking Alpha - 1 year ago

Trevi Therapeutics: A Promising Pruritus Player In 2020

Zacks Investment Research - 1 year ago

Trevi Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 1 year ago

NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of n...

Benzinga - 1 year ago

Trevi Therapeutics Inc (NASDAQ: TRVI) priced its 5.5 million share IPO at $10 May 7, and shares have been mostly trading at a discount since then.

About TRVI

Trevi Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Its Haduvio (nalbuphine ER), which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with ... [Read more...]

Industry
Biotechnology
IPO Date
May 7, 2019
CEO
Jennifer L. Good
Employees
22
Stock Exchange
NASDAQ
Ticker Symbol
TRVI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price forecast is 11.00, which is an increase of 270.37% from the latest price.

Price Target
$11.00
(270.37% upside)
Analyst Consensus: Strong Buy